天津医科大学最新Cell子刊：这个基因可增强二甲双胍对肺癌的抗肿瘤作用

Core Viewpoint - The study highlights the role of C19orf12 as a mitochondrial metabolic regulator in non-small cell lung cancer (NSCLC), indicating that elevated expression levels may serve as a biomarker for improved response to metformin treatment [10]. Group 1: Research Findings - C19orf12 is highly expressed in NSCLC and is associated with poor prognosis [7]. - C19orf12 regulates mitochondrial function and drives glucose metabolic reprogramming [7]. - C19orf12 interacts with LRPPRC protein, downregulating the expression of mitochondrial electron transport chain complexes I and IV [7]. - High levels of C19orf12 inhibit mitochondrial respiration and reduce glucose flux through the tricarboxylic acid (TCA) cycle [5][6]. Group 2: Implications for Treatment - C19orf12 enhances the sensitivity of NSCLC cells to the antitumor effects of metformin [6]. - The study suggests that C19orf12 expression levels could predict the response to metformin treatment in NSCLC patients [10].